Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × tucatinib × Clear all

Phase

Phase 2 2 Phase 1/2 2 Phase 1 1

Status

Recruiting 3 Completed 3 Withdrawn 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 30 Radiotherapy 21 Cisplatin 21 fludarabine 19 Paclitaxel 19 Nivolumab 17 Magnetic Resonance Spectroscopy 16 Carboplatin 16 pembrolizumab 15 fludarabine phosphate 14 Specimen Handling 14 Gemcitabine 14 Biopsy 12 Radiation 11 Docetaxel 10 Cytarabine 10 Radiosurgery 9 Melphalan 9 Filgrastim 9 Etoposide 9 Doxorubicin 9 Dexamethasone 9 Ipilimumab 8 Granulocyte Colony-Stimulating Factor 8 venetoclax 7 trametinib 7 ibrutinib 7 durvalumab 7 Sorafenib 7 Rituximab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Dana-Farber Cancer Institute

Phase 1 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡